Deciphera Pharmaceuticals, Inc. (DCPH) announced the UK Medicines and Healthcare products Regulatory Agency has granted marketing authorization for QINLOCK in the UK for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib.

Create Account

Dark

chart

exchange

Check out our Level2View

Deciphera Pharmaceuticals, Inc. (DCPH) announced the UK Medicines and Healthcare products Regulatory Agency has granted marketing authorization for QINLOCK in the UK for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib.

RTTNews | Dec 21, 2021 08:56AM EST

08:56 Tuesday, December 21, 2021 (RTTNews.com) - Deciphera Pharmaceuticals, Inc. (DCPH) announced the UK Medicines and Healthcare products Regulatory Agency has granted marketing authorization for QINLOCK in the UK for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib.

The company said the QINLOCK approval was supported by efficacy results from the primary analysis of the pivotal phase 3 INVICTUS study in patients with advanced gastrointestinal stromal tumor and combined safety results from INVICTUS and the phase 1 study of QINLOCK.

Read the original article on RTTNews ( https://www.rttnews.com/3250854/deciphera-pharma-reports-approval-of-qinlock-in-the-uk-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved